Recent News for SCYX - SCYNEXIS, Inc.

Date Title
Oct 10 SCYNEXIS to Strengthen its Balance Sheet with Non-Dilutive Funding Through the New Jersey Economic Development Authority Net Operating Loss and R&D Tax Credits Program
Oct 2 SCYNEXIS to Present Data at IDWeek 2019 and the 9th Congress on Trends in Medical Mycology (TIMM-9) Highlighting Scientific and Clinical Evidence of Ibrexafungerp's Activity Against Resistant Fungal Pathogens, Including Candida auris
Oct 1 Does SCYNEXIS (NASDAQ:SCYX) Have A Healthy Balance Sheet?
Oct 1 Antimicrobials Working Group Highlights Member Company Participation at IDWeek 2019
Sep 18 FDX, MDR, PTCT and ROAD among midday movers
Sep 18 Scynexis up 11% on advancement of late-stage study of antifungal ibrexafungerp
Sep 18 SCYNEXIS Completes Last-Patient/Last-Visit Ahead of Schedule in the First Phase 3 Study (VANISH 303) of Oral Ibrexafungerp for the Treatment of Vulvovaginal Candidiasis (VVC)
Sep 4 SCYNEXIS, Inc. to Participate in Two Upcoming Investor Conferences
Aug 21 Implied Volatility Surging for SCYNEXIS (SCYX) Stock Options
Aug 20 Piper upgrades AbbVie in premarket analyst action
Aug 14 Puissance Capital Management LP Buys SCYNEXIS Inc
Aug 14 Does SCYNEXIS, Inc.'s (NASDAQ:SCYX) CEO Salary Reflect Performance?
Aug 7 Scynexis (SCYX) Reports Q2 Loss, Misses Revenue Estimates
Aug 7 SCYNEXIS EPS beats by $0.03, revenue in-line
Aug 7 SCYNEXIS Reports Second Quarter 2019 Financial Results and Provides Company Update
Aug 1 Scynexis (SCYX) May Report Negative Earnings: Know the Trend Ahead of Q2 Release
Jul 31 SCYNEXIS, Inc. to Present at the 39th Annual Canaccord Genuity Global Growth Conference
Jul 25 What Scynexis' Trial Protocol News Says About Its Market Estimate
Jul 24 S, SNAP among premarket gainers
Jul 24 SCYNEXIS Announces Special Protocol Assessment (SPA) Agreement with FDA for Phase 3 Study Evaluating Oral Ibrexafungerp for the Prevention of Recurrent Vulvovaginal Candidiasis (VVC) (CANDLE Study)
Jul 20 Key Takeaways From A Follow-Up Phone Call With Scynexis CEO
Jul 4 Scynexis: Updates To Thesis, Expecting Rebound In The Near Term
Jul 1 X-Biotix Therapeutics Joins Antimicrobials Working Group
Jun 25 World-renowned Fungal Infection Expert Comments on Oral Ibrexafungerp Data Presented by SCYNEXIS at ASM Microbe 2019
Jun 20 Antimicrobials Working Group Highlights Member Company Participation at ASM Microbe 2019
Back to the Main SCYX Page...